Skip to content

Mindful Walking in Low Back Pain

Effectiveness of a a Mindful Walking Program in Patients With Chronic Low Back Pain - a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01893073
Acronym
MW-LBP
Enrollment
48
Registered
2013-07-08
Start date
2013-06-30
Completion date
Unknown
Last updated
2014-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Low Back Pain

Brief summary

The purpose of this study is to determine whether a mindful walking program is effective in the treatment of patients with chronic low back pain.

Interventions

BEHAVIORALMindful walking program

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* male and female, 18-65 years * chronic low back pain (disease duration \> 3 months) * pain intensity on visual analogue scale at inclusion \> 40 mm (0-100 mm scale) * only pharmacological treatment with NSAID or no treatment in the last 4 weeks * undersigned informed consent form

Exclusion criteria

* active walking or jogging in the last 6 weeks (\< 60 minutes/week) * regular meditation, relaxation exercise, mindfulness exercise in last 6 weeks (\> 30 minutes per week) * use of complementary medicine therapies as acupuncture, homeopathy, herbal medicine in last 6 weeks or planned in the next 12 weeks * use of other nonpharmacological therapies as physical therapy, manual therapy or osteopathy in the last 4 weeks * participation in another trials within the last 3 months * pathological neurological symptoms such as muscular paralysis or paraesthesia due to spinal disc herniation or other causes * risk of falls and inability to walk * angina pectoris in the last 3 months * chronic respiratory disease with respiratory insufficiency * intake of central nervous system-acting analgesics in the last 6 weeks * Known renal and / or hepatic diseases * Severe organic, psychological or psychiatric disorders that are not permitting a study participation * applying for early retirement due to low back pain * no undersigned informed consent form

Design outcomes

Primary

MeasureTime frame
Pain intensity on visual analogue scale8 weeks

Secondary

MeasureTime frame
Pain intensity on visual analogue scale12 weeks
Cohens perceived stress scale8 weeks, 12 weeks
Back function - FFbH-R-Questionnaire8 weeks, 12 weeks
Intake of paracetamol8 weeks
Adverse events8 weeks, 12 weeks
Quality of Life - SF 368 weeks, 12 weeks

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026